Next Science Limited
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more
Next Science Limited (NXSCF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 5.179x
Based on the latest financial reports, Next Science Limited (NXSCF) has a cash flow conversion efficiency ratio of 5.179x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.88 Million) by net assets ($-557.03K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Next Science Limited - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Next Science Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Next Science Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Next Science Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lux Metals Corp.
F:GP80
|
-0.555x |
|
Reallusion Inc.
TWO:6882
|
-0.082x |
|
Canoo Inc
NASDAQ:GOEV
|
-0.119x |
|
Medadvisor Ltd
AU:MDR
|
5.093x |
|
Austem Company Ltd
KQ:031510
|
-0.003x |
|
United Lithium Corp
OTCQX:ULTHF
|
-0.002x |
|
Nidaros Sparebank
OL:NISB
|
N/A |
|
Dev Information Technology Limited
NSE:DEVIT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Next Science Limited (2016–2024)
The table below shows the annual cash flow conversion efficiency of Next Science Limited from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.44 Million | $-7.96 Million | -2.313x | -96.95% |
| 2023-12-31 | $12.82 Million | $-15.06 Million | -1.175x | -18.05% |
| 2022-12-31 | $11.85 Million | $-11.79 Million | -0.995x | -29.22% |
| 2021-12-31 | $10.73 Million | $-8.26 Million | -0.770x | -8.44% |
| 2020-12-31 | $18.80 Million | $-13.35 Million | -0.710x | -10.22% |
| 2019-12-31 | $19.37 Million | $-12.48 Million | -0.644x | -31.02% |
| 2018-12-31 | $23.74 Million | $-11.67 Million | -0.492x | -1532.03% |
| 2017-12-31 | $3.61 Million | $-108.77K | -0.030x | +98.28% |
| 2016-12-31 | $1.34 Million | $-2.35 Million | -1.751x | -- |